← Leaderboards
Joseph Michael Wallace
Rlr Va Medical Center
$3,017,414
Attributed
$4,589,683
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $990.3K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,589,683 · 5
VA$0 · 1
By mechanism
R01$4,077,044 · 3
K25$419,013 · 1
F32$93,626 · 1
I01$0 · 1
Top collaborators
- Thomas Levin Geiser Andersen3 shared
- Ryan Dee Ross3 shared
- Matthew R Allen2 shared
- Sharon M Moe2 shared
Most similar at Rlr Va Medical Center
Same institution · by research overlap
- Matthew R Allen$4,949,850
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTissuesFractureBonePropertyBone DiseasesPharmaceutical PreparationsIn VivoInnovationMineralsSurfaceBone TissueCollagenMechanicsPhysical PropertyBone MatrixMineralizationSkeletalBiologyLaboratoriesPharmacologic SubstanceRaloxifeneBone FatigueMolecular
Grant awards (18)
Uremic toxins and osteocyte dysfunction in CKD$550,066
R01 · FY2025 · DK
How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures$353,132
R01 · FY2025 · AR
Improving bone mass and quality in comorbid diabetes and chronic kidney disease$0
I01 · FY2025 · VA · contact PI
Uremic toxins and osteocyte dysfunction in CKD$598,846
R01 · FY2024 · DK
How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures$391,487
R01 · FY2024 · AR
Improving bone mass and quality in comorbid diabetes and chronic kidney disease$0
I01 · FY2024 · VA · contact PI
How bisphosphonates affect bone matrix and remodeling: implications for atypical femoral fractures$464,873
R01 · FY2023 · AR
Improving bone mass and quality in comorbid diabetes and chronic kidney disease$0
I01 · FY2023 · VA · contact PI
Targeting collagen as an interventional approach to improve bone material properties$343,035
R01 · FY2022 · AR · contact PI
Targeting collagen as an interventional approach to improve bone material properties$336,105
R01 · FY2021 · AR · contact PI
Targeting collagen as an interventional approach to improve bone material properties$346,500
R01 · FY2020 · AR · contact PI
Targeting collagen as an interventional approach to improve bone material properties$346,500
R01 · FY2019 · AR · contact PI
Targeting collagen as an interventional approach to improve bone material properties$346,500
R01 · FY2018 · AR · contact PI
Mechanical Protection of Pathological Collagen Synthesis$139,671
K25 · FY2017 · AR · contact PI
Mechanical Protection of Pathological Collagen Synthesis$139,671
K25 · FY2016 · AR · contact PI
Mechanical Protection of Pathological Collagen Synthesis$139,671
K25 · FY2015 · AR · contact PI
Investigating Ultrastructural Collagen Changes in Osteogenesis Imperfecta$48,010
F32 · FY2009 · DE · contact PI
Investigating Ultrastructural Collagen Changes in Osteogenesis Imperfecta$45,616
F32 · FY2008 · DE · contact PI